Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2021 at "Infectious diseases and therapy"
DOI: 10.1007/s40121-021-00542-3
Abstract: Introduction The aim of the present study was to assess the safety profile and outcomes of a ceftazidime-avibactam (CAZ-AVI)-based regimen and compare them with those of a tigecycline (TGC)-based regimen in intensive care unit (ICU)…
read more here.
Keywords:
caz avi;
treatment;
group;
critically ill ... See more keywords
Photo from archive.org
Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal of global antimicrobial resistance"
DOI: 10.1016/j.jgar.2020.10.014
Abstract: OBJECTIVE To correlate results of a modified susceptibility testing method to outcomes of ceftazidime-avibactam (CAZ/AVI) therapy. METHODS Two bloodstreamK. pneumoniae isolates (CAZ/AVI susceptible) from an abdominal source were recovered from 2 unrelated patients. Both patients…
read more here.
Keywords:
ceftazidime avibactam;
caz avi;
mic profiling;
caz ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2022 at "Journal of global antimicrobial resistance"
DOI: 10.1016/j.jgar.2022.02.018
Abstract: BACKGROUND Ceftazidime/avibactam (CAZ/AVI) has shown in vitro activity against multidrug-resistant (MDR) Gram-negative bacteria, especially Enterobacterales and carbapenem-resistant Pseudomonas aeruginosa. However, in vitro activity of CAZ/AVI against Gram-negative bacteria in Colombian hospitals is still unknown. The…
read more here.
Keywords:
gram negative;
vitro activity;
caz avi;
activity ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.1495
Abstract: Carbapenemases confer resistance against a broad range of beta-lactams with a prevalence of 40-60% among CRE (carbapenem-resistant Enterobacteriaceae). CAZ-AVI is commonly used to treat infections due to CPE (carbapenemase-producing Enterobacteriaceae), typically guided by susceptibility testing…
read more here.
Keywords:
carbapenemase producing;
caz avi;
mic profiling;
caz ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.1760
Abstract: Ceftazidime-avibactam (CAZ-AVI) is a β-lactam/non-β-lactam β-lactamase inhibitor combination with in vitro activity against Enterobacterales (Ent) and Pseudomonas aeruginosa (Psa) carrying Class A, C and some Class D β-lactamases. We examined the in vitro activity of…
read more here.
Keywords:
caz avi;
pfizer;
employee;
vitro activity ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.1784
Abstract: To estimate the cost-effectiveness of ceftazidime-avibactam (CAZ-AVI) for the treatment of hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP) caused by multi-drug resistant enterobacteriaceae (MDRE) or MDR pseudomonas aeruginosa (MDRPA) in China. A previously published patient-level…
read more here.
Keywords:
caz avi;
effectiveness ceftazidime;
pfizer;
cost ... See more keywords
Photo by lowie from unsplash
Sign Up to like & get
recommendations!
0
Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.897
Abstract: Abstract Background Ceftazidime-avibactam (CAZ-AVI) and ceftolozane-tazobactam (TOL-TAZ) are cephalosporin/β-lactamase inhibitor combinations recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). Both agents are reported to have antibacterial activity…
read more here.
Keywords:
lactamase;
caz avi;
tol taz;
lactamase producing ... See more keywords
Photo by cdc from unsplash
Sign Up to like & get
recommendations!
0
Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.923
Abstract: Abstract Background Early detection of carbapenem-resistant Enterobacteriaceae(CRE) is crucial for selection of effective treatment. While KPC is the most prevalent carbapenemase in the US, phenotypic screening methods, such as the carbapenemase inactivation method (CIM) and…
read more here.
Keywords:
caz avi;
producing organisms;
disk;
mer ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.1216
Abstract: Abstract Background Novel antibiotics will not be available to combat the threat of MBLs until 2021. One strategy to overcome MBLs is to combine CAZ-AVI + ATM. ATM is not hydrolysed by MBLs and AVI…
read more here.
Keywords:
combination;
168 hours;
caz avi;
infusion ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.1253
Abstract: Abstract Background The new β-lactamase inhibitor, avibactam (AVI), has recently been combined with ceftazidime (CAZ) as CAZ-AVI. AVI is also in Phase 3 clinical trials combined with aztreonam as ATM-AVI. Both drug combinations have similar…
read more here.
Keywords:
100 100;
caz avi;
atm avi;
avi ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.2101
Abstract: Abstract Background The dissemination of multi-drug-resistant Enterobacteriaceae (MDR Eba) threatens the treatment of Gram-negative infections. Ceftazidime–avibactam (CAZ-AVI) is a novel antimicrobial with activity against Eba producing Class A, C and some Class D β-lactamases. This…
read more here.
Keywords:
caz avi;
caz;
vitro activity;
tract ... See more keywords